(In July 10 story, corrects paragraph 6 to say “has reached an agreement on protocol revisions to restart enrollment” instead of “it would restart enrollment”)
Edwards Lifesciences Corp said it would buy privately held heart device maker CardiAQ Valve Technologies Inc for up to $400 million to expand its portfolio of less-invasive mitral valve replacement devices.
The deal comes nearly two months after Edwards stopped enrolling patients for a study of its less-invasive mitral heart valve device, Fortis.
The company will pay $350 million in cash for CardiAQ and the rest will be paid on achievement of certain regulatory milestones.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Edwards launched a catheter-based aortic valve replacement device in the United States in 2011 and it is now trying to adapt the technology for mitral valves.
Transcatheter products, which allow the valve to be threaded through the arteries to the heart, provide an alternative to open-heart surgery.
Edwards said on Friday it has reached an agreement with its clinical investigators on protocol revisions to restart enrollment for the study. The company said it expected the CardiAQ deal to be slightly dilutive to 2015 earnings.
The Irvine, California-based company’s shares closed at $147.16 on the New York Stock Exchange on Friday.
Date: March 18, 2019
Source: Reuters
